TrialThe Lancet. Oncology2015

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Antoni Ribas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.